Venmax Drugs & Pharmaceuticals Ltd Financials
Company Logo

Venmax Drugs & Pharmaceuticals Ltd Financial Statement

Venmax Drugs & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2025
Revenue1.21
Operating Expense1.17
Net Profit0.04
Net Profit Margin3.31
Earning Per Share0.07
EBIDTA0.04
Effective Tax RateTBA

Venmax Drugs & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Total Revenue Annual0.81
Operating Expenses Annual1.87
Operating Profit Annual-0.01
Interest Annual0.00
DepreciationTBA
Net Profit Annual-0.01
Tax Annual-0.00

Venmax Drugs & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Cash Flow at the BeginningTBA
Cash Flow from Operations-2.29
Cash Flow from InvestingTBA
Cash Flow from Financing4.77
Cash Flow at the End2.48

Venmax Drugs & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
PBDIT Margin (%)14.81
PBIT Margin (%)13.58
PBT Margin (%)13.58
Net PROFIT Margin (%)-1.23
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)-0.48
Total Debt / Equity (X)0.11
Asset Turnover Ratio (%)0.39

Venmax Drugs & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2025
Fixed Assets Annual0.04
Total Current Assets Annual5.13
Non Current Assets Annual0.04
Total Shareholders Funds Annual4.41
Total Assets Annual5.17

Venmax Drugs & Pharmaceuticals Ltd Earning Calls

No Data Availabe

FAQS on Venmax Drugs & Pharmaceuticals Ltd Financials

As of Oct 5, 2025, Venmax Drugs & Pharmaceuticals Ltd has a market capitalization of 14.94 Cr. Value Research classifies it as a Micro-Cap company.

Yes, Venmax Drugs & Pharmaceuticals Ltd is with a debt-to-equity ratio of 0.01.

In FY 2024 , Venmax Drugs & Pharmaceuticals Ltd recorded a total revenue of approximately 0.81 Cr marking a significant milestone in the company's financial performance.

Venmax Drugs & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and Infinity% annually, respectively..

Venmax Drugs & Pharmaceuticals Ltd's current PE ratio is -1494.00.

Venmax Drugs & Pharmaceuticals Ltd's ROCE averaged -30.6% from the FY ending March 2023 to 2025, with a median of -29.2%. It peaked at -0.3% in March 2025, reflecting strong capital efficiency over the period..

Venmax Drugs & Pharmaceuticals Ltd's latest EBIT is Rs. -0.01 Cr, surpassing the average EBIT of Rs. 0.10 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions